Skip to content

The real study of thymus method combined with immune checkpoint inhibitor in the clinical treatment of cancer

The real study of thymus method combined with immune checkpoint inhibitor in the clinical treatment of cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400087709
Enrollment
Unknown
Registered
2024-08-01
Start date
2024-08-01
Completion date
Unknown
Last updated
2024-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant tumor

Interventions

Control group:None
Observation group:None

Sponsors

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1.Patients with advanced malignant tumors confirmed by pathologiccytology combined with previous history and current history; 2.patients over 18 years old, regardless of gender; 3. KPS score greater than 70% or ECOG score less than 1 point; 4.Malignant tumor patients treated with immune checkpoint inhibition; 5.Normal function of major organs: normal thyroid function, normal cardiacfunction (normal range of cardiac troponin, normal electrocardiogram); 6.Renal function needs to meet: serum creatinine value is less than the upperlimit of normal value, endogenous creatinine clearance rate is not less than60ml/min, glomerular filtration The rate is not less than 60ml/min; Liver function: total bilirubin<1.5 times the upper limit; Liver enzymes <1.5 times upper limit; 7.No history of immune-related diseases, such as SLE, autoimmunehepatitis, rheumatoid arthritis, vasculitis, etc. 8. Good compliance and voluntarily accepted follow-up, treatment, laboratory examination and imaging evaluation as planned

Exclusion criteria

Exclusion criteria: 1Patients with known intolerance to thymofasine and immune checkpoint inhibitors; 2Combination of severe and uncontrolled conditions that have occurred in the past as a result oftreatment or disease progression symptoms; 3The presence of unresolved baseline or grade 1 adverse eventsassociated with previous PD-1 treatment; 4Patients requiring maintenance therapy with immunosuppressants, such as thoseundergoing organ transplantation.

Design outcomes

Secondary

MeasureTime frame
Immune cell and molecular counts;

Primary

MeasureTime frame
PFS;ORR;Incidence of adverse reactions;

Countries

China

Contacts

Public ContactLi Ruichao

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

liruichao@126.com+86 138 8617 1191

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026